Jane Street
GTBP icon

Jane Street’s GT Biopharma GTBP Stock Holding History

Jane Street’s Portfolio GTBP Stock Details GTBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-26,016
Closed -$20.4K – 12117
2025
Q4 		$20.4K Buy
+26,016
New +$18.5K ﹤0.01% 10723
2024
Q1 		– Sell
-647
Closed -$4.95K – 9540
2023
Q4 		$4.95K Buy
+647
New +$4.73K ﹤0.01% 9018
2023
Q3 		– Sell
-683
Closed -$6.4K – 8913
2023
Q2 		$6.4K Sell
683
-1,004
-60% -$10.4K ﹤0.01% 8479
2023
Q1 		$27.8K Sell
1,687
-110
-6% -$2.52K ﹤0.01% 8586
2022
Q4 		$47.8K Buy
1,797
+706
+65% +$35.3K ﹤0.01% 8384
2022
Q3 		$58K Buy
+1,091
New +$83.4K ﹤0.01% 8876

Other funds holding GTBP

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
AAP
Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SWM
SeaCrest Wealth Management Purchase, New York $903M AUM 47.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
I
INVST Indianapolis, Indiana $1.03B AUM 29.49% 1-Year Est. Return

Jane Street's GTBP Position: Q1 2026 in Review

Jane Street sold out of GT Biopharma (GTBP) in Q1 2026, closing a stake of 26,016 shares — an estimated $20.4K sold.

Jane Street first reported a position in GTBP in Q3 2022 and held it in 6 quarters. The position peaked at $58K in Q3 2022. 42 funds tracked by Wall St. Rank hold GTBP as of Q1 2026.

  • Jane Street reported no remaining GT Biopharma position as of Q1 2026 after selling out during the quarter.
  • Jane Street sold 26,016 GT Biopharma shares in Q1 2026, an estimated $20.4K.
  • Jane Street first reported a position in GT Biopharma in Q3 2022 and held it in 6 quarters.
  • Jane Street's GT Biopharma position peaked at $58K in Q3 2022.
  • 42 funds tracked by Wall St. Rank held GT Biopharma as of Q1 2026.

Based on Jane Street's 13F filing for Q1 2026, filed 12 May 2026.